Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 1.00 |
| ▸ | RXRB | P28702 | 8/20 | 1.00 |
| ▸ | RARB | P10826 | 13/20 | 0.72 |
| ▸ | RARG | P13631 | 12/20 | 0.72 |
| ▸ | RXRG | P48443 | 6/20 | 0.72 |
| ▸ | RARA | P10276 | 9/20 | 0.68 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | GMNN | O75496 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827631 | 0.87 | RARB (0.81) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL846110 | 0.87 | RARB (0.81) | RXRARXRBRARBRARGRXRG | |
| Hydrochloric Acid SCHEMBL9120757 | 0.85 | RARB (0.78) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL9319026 | 0.84 | RXRA (0.77) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL10355871 | 0.84 | RXRA (1.00) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL3454328 | 0.84 | RXRA (1.00) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL7421190 | 0.84 | RXRA (0.72) | RXRARXRBRARBRARGRXRG | |
| Hydrazine SCHEMBL9430381 | 0.83 | RARB (0.76) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8610553 | 0.82 | RXRA (0.70) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL21082224 | 0.82 | RXRA (0.69) | RXRARXRBRARBRARGRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240299329-A1 | PRECURSOR COMPOUNDS FOR PROVIDING RETINOIDS OF THE VATAMIN A5 PATHWAY AND USES THEREOF | UNIV OF DEBRECEN (HU) | 2024-09-12 | — | — | US | disclosed |
| US-12029715-B2 | Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof | UNIVERSITY OF DEBRECEN (HU) | 2024-07-09 | — | — | US | disclosed |
| US-20240009101-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20230404886-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| CN-117243839-A | Minoxidil adjuvant therapy | 应用生物学股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11766392-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-6083973-A | ADMINISTERING TO THE MAMMAL RETINOIC ACID RECEPTOR ANTAGONIST OR PRODRUG TO PREVENT MUCIN PRODUCTION | SYNTEX (U.S.A.) INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1999045915-A1 | USE OF ALPHA-RAR ANTAGONISTS FOR INHIBITION OF MUCIN SECRETION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-16 | — | — | WO | disclosed |
| US-5650279-A | ISOLATED POLYNUCLEOTIDE WHICH SPECIFICALLY BINDS TAZAROTENE INDUCIBLE GENE | ALLERGAN, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5552271-A | SCREENING FOR SUBSTANCES WHICH INDUCE FORMATION OF RETINOID XRECEPTOR HOMODIMERS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996023080-A1 | GENE SEQUENCE INDUCED IN SKIN BY RETINOIDS | ALLERGAN (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1995033745-A9 | NOVEL COMPOUNDS USEFUL IN MODULATING GENE EXPRESSION OF RETINOID RESPONSIVE GENES AND/OR HAVING ANTI-AP-1 ACTIVITY | — | 1996-01-18 | — | — | WO | disclosed |
| WO-1995033745-A2 | NOVEL COMPOUNDS USEFUL IN MODULATING GENE EXPRESSION OF RETINOID RESPONSIVE GENES AND/OR HAVING ANTI-AP-1 ACTIVITY | SRI INTERNATIONAL (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5466861-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0671005-A1 | RXR HOMODIMER FORMATION AND BRIDGED BICYCLIC AROMATIC COMPOUNDS AND THEIR USE IN MODULATING GENE EXPRESSION | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012880-A2 | RXR HOMODIMER FORMATION AND BRIDGED BICYCLIC AROMATIC COMPOUNDS AND THEIR USE IN MODULATING GENE EXPRESSION | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029715-B2 | Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof | RXRA, RXRG, RARA | RXRA 1/4885RXRB 4/4885RARB 6/4885 |
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RARB 4/4885 |
| US-20240299329-A1 | PRECURSOR COMPOUNDS FOR PROVIDING RETINOIDS OF THE VATAMIN A5 PATHWAY AND USES THEREOF | RXRA, RARA, RXRG | RXRA 1/4885RXRB 4/4885RARB 6/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | RXRA 2/4885RXRB 3/4885RARB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.